Subscribe or Manage Preferences

Gasterol Intestinal Symposium

San Francisco, CA—For resectable pancreatic cancer, administering chemo - therapy and radiation before surgery results in better outcomes and lower costs than performing surgery first, reported researchers from M.D. Anderson Cancer Center, Houston. "Compared with a surgery-first approach, the neoadjuvant approach eliminates an ineffectual, costly, and potentially morbid treatment in patients with early metastases or a prohibitive function status. It is associated with improved survival, and it costs less per patient," said lead investigator Daniel Erik Abbott, MD.

San Francisco, CA—Results obtained on the Oncotype DX Colon Cancer Assay led to changes in treatment decisions 29% of the time for patients with stage II colon cancer, according to a survey of community oncologists reported at the 2012 Gastrointestinal Cancers Symposium. "One of the more difficult decisions is what stage II patients to treat," said lead investigator Thomas H. Cartwright, MD, Ocala Oncology, FL. "In stage II patients, we typically rely on more subjective factors, number of lymph nodes, tumor grade, and so forth.

San Francisco, CA—Using a prediction model to analyze the impact of adding targeted agents to the treatment of pancreatic neuroendocrine tumors (pNETs), everolimus (Afinitor) had a minimal overall impact on healthcare expenditures, by reducing infusions and surgical procedures costs, according to a study presented at the 2012 Gastrointestinal Cancers Symposium. For patients with advanced pNETs, the median overall survival is typically approximately 2 years.


Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology